Yesterday, we held a meeting with the investment community to review growth strategies for Johnson & Johnson’s pharmaceuticals business. It was an in-depth look at how our employees and partners across the world are working to address major unmet needs in a number of areas, and developing an amazing pipeline of new medicines. Sheri McCoy, vice chairman of the Executive Committee, spoke about meeting needs with science and increasing the capacity to treat patients, saying , “We have the opportunity to make a difference for people around the world.”
Paul Stoffels, M.D., also provided an overview of the strength of the pharmaceuticals pipeline, and Joaquin Duato reviewed the commercial strategies that have enabled our pharmaceuticals businesses to become launch leaders in several categories. Paul and Joaquin are both Worldwide Chairmen, Pharmaceuticals. The Company highlighted the expectations of its pharmaceuticals businesses to file 11 new products and more than 30 line extensions in the next five years.
The R&D leaders took investors on a deeper dive in five therapeutic areas: neuroscience, cardiovascular and metabolism, immunology, oncology and infectious diseases and vaccines. They spoke about recent product approvals, the strength of the pharmaceuticals pipeline in these areas, and the geographic reach of the business, both in established markets and in emerging markets.
Some of the main highlights were:
• The Company’s pharmaceuticals business is in the process of launching six key pharmaceutical products since 2009 and is advancing key compounds in our pipeline.
• The pharmaceuticals business is leveraging global market strategies and using local insights to meet unmet needs worldwide and expand its geographic presence.
• The pharmaceuticals business segment is very well positioned for global growth.